

ORAL PRESENTATION

Open Access

Overcoming the affordability barrier for effective and high quality life saving malaria medicines in the private sector in rural Uganda: the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study

Ambrose O Talisuna^{1,2*}, Penny Grevhal¹, Andrew Balyeku¹, Timothy Egan¹, Godfrey Bwire¹, Bram Piot¹, Renia Coghlan¹, Maud Lugand¹, John Bosco Rwakimari³, Richard Ndyomugenyi³, Fred Kato³, Maria Byangire³, Paul Kagwa³, Fred Sebisubi³, David Nahamya⁴, Angela Bonabana⁴, Susan Mpanga-Mukasa⁵, Peter Buyungo⁵, Julius Lukwago⁵, Allan Batte⁵, Grace Nakanwagi⁶, James Tibenderana⁶, Kinny Nayer⁷, Kishore Reddy⁷, Nilesh Dokval⁷, Sylvester Rugumambaju⁸, Saul Kidde⁹, Jaya Banerji¹, George Jagoe¹

From Challenges in malaria research
Basel, Switzerland. 10-12 October 2012

Background

Artemisinin-based combination therapies (ACTs), the treatment of choice for non-complicated falciparum malaria, are unaffordable and inaccessible in the private sector, yet the private sector is the first port of call for malaria treatment across most of rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to effective malaria treatment could be improved through the provision of highly subsidized ACTs in the private sector.

Methods

Four intervention districts (Pallisa, Budaka, Kamuli and Kaliro) were purposefully selected to receive branded subsidized medicines—"ACT with a leaf", while the fifth district (Soroti) acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at all licensed private drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention's impact on: ACT uptake; access to ACTs within 24 hours of symptom-onset; and displacement of sub-optimal antimalarials.

Results

At baseline, the market share of ACTs was < 1%. However, at evaluation, "ACT with a leaf" had a market share of 69% in the interventions districts. Access to ACTs within 24 hours of symptom onset rose from 0.8% at baseline to 26.2% (95% CI: 23.2 - 29.2%) at evaluation in the intervention districts. In the control district it modestly rose from 1.8% to 5.6% (95% CI: 4.0 - 7.3%). The odds of accessing ACTs within 24 hours in the intervention compared to the control districts was 0.46 (95% CI: 0.08 - 2.68, $p = 0.4$), at baseline and significantly increased to 6.11 (95% CI: 4.32 - 8.62, $p < 0.0001$) at evaluation. Children less than 5 years-old had "ACT with a leaf" purchased for them more often than those aged above 5 years. There was no evidence of price gouging.

Conclusions

Our data demonstrate that a supply-side antimalarial subsidy coupled with an intensive communications campaign significantly increased the uptake of ACTs in the private sector in Uganda.

Author details

¹Medicines for Malaria Venture-MMV. ²Malaria Public Health & Epidemiology Cluster, University of Oxford-KEMRI-Wellcome Trust Research Programme and Worldwide Antimalarial Resistance Network-WWARN. ³Uganda Ministry of Health-Ug-MoH. ⁴Uganda National Drug Authority-NDA. ⁵Programme for Accessible Health Communication and Education-PACE. ⁶Malaria Consortium-MC.

¹Medicines for Malaria Venture-MMV
Full list of author information is available at the end of the article

⁷Surgipharma Pharmaceuticals. ⁸I+Solutions. ⁹Management Sciences for Health-MSH.

Published: 15 October 2012

doi:10.1186/1475-2875-11-S1-O16

Cite this article as: Talisuna *et al.*: Overcoming the affordability barrier for effective and high quality life saving malaria medicines in the private sector in rural Uganda: the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study. *Malaria Journal* 2012 11(Suppl 1):O16.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

